Lilly targets quarterly deals worth up to $5bn to boost R&DEli Lilly is targeting a deal worth between $1 billion to $5 billion every quarter in 2020 as Share XLilly targets quarterly deals worth up to $5bn to boost R&Dhttps://pharmaphorum.com/news/lilly-targets-quarterly-deals-worth-up-to-5bn-boost-rd/
UK accounts for 12% of cell and gene therapy trials – reportThe UK accounts for over 12% of global cell and gene therapy clinical trials, according to new data Share XUK accounts for 12% of cell and gene therapy trials – reporthttps://pharmaphorum.com/news/uk-accounts-for-12-of-cell-and-gene-therapy-trials-report/
MorphoSys gets $750m from Incyte for anti-CD19 cancer drugIncyte has agreed a deal with Germany’s MorphoSys to license an antibody that could be an alternative to Share XMorphoSys gets $750m from Incyte for anti-CD19 cancer drughttps://pharmaphorum.com/news/morphosys-gets-750m-from-incyte-for-anti-cd19-cancer-drug/
GSK’s CEO Walmsley aiming for six new approvals in 2020GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in Share XGSK’s CEO Walmsley aiming for six new approvals in 2020https://pharmaphorum.com/news/gsks-ceo-walmsley-aiming-for-six-new-approvals-in-2020/
Chasing Astellas, UK’s KaNDy heads to phase 3 with menopause drugUK biotech KaNDy Therapeutics is heading to phase 3 with its non-hormonal menopause drug, after a mid-stage trial Share XChasing Astellas, UK’s KaNDy heads to phase 3 with menopause drughttps://pharmaphorum.com/news/chasing-astellas-uks-kandy-heads-to-phase-3-with-menopause-drug/
AZ axes phase 3 heart disease trial of fish oil drug EpanovaAstraZeneca has axed a large late-stage trial for its heart disease drug Epanova in patients with mixed dyslipidemia Share XAZ axes phase 3 heart disease trial of fish oil drug Epanovahttps://pharmaphorum.com/news/az-axes-phase-3-trial-in-heart-disease/
Lilly swoops on Dermira to claim Dupixent rivalEli Lilly agreed on Friday to buy dermatology specialist Dermira for $1.1 billion and its lead drug, a Share XLilly swoops on Dermira to claim Dupixent rivalhttps://pharmaphorum.com/news/lilly-swoops-on-dermira-to-claim-dupixent-rival/
Neurocrine signs $400M-plus deal with Idorsia for epilepsy drugSwiss biotech Idorsia and Neurocrine Biosciences of the US have amended a deal signed last year to develop Share XNeurocrine signs $400M-plus deal with Idorsia for epilepsy drughttps://pharmaphorum.com/news/neurocrine-signs-400m-plus-deal-with-idorsia-for-epilepsy-drug/
AI specialist Exscientia signs drug discovery tie-up with BayerUK artificial intelligence company Exscientia has added another big pharma company to its partner roster, with Bayer seeking Share XAI specialist Exscientia signs drug discovery tie-up with Bayerhttps://pharmaphorum.com/news/ai-specialist-exscientia-signs-drug-discovery-tie-up-with-bayer/
BI buys rights to NASH-targeted tech from Singapore’s EnleofenBoehringer Ingelheim has bought rights to preclinical technology aimed at fibro-inflammatory diseases including the fatty liver disease known Share XBI buys rights to NASH-targeted tech from Singapore’s Enleofenhttps://pharmaphorum.com/news/bi-buys-rights-to-nash-targeted-tech-from-singapores-enleofen/
Ligelizumab could top Xolair in chronic hives, says NovartisNovartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many Share XLigelizumab could top Xolair in chronic hives, says Novartishttps://pharmaphorum.com/news/ligelizumab-could-top-xolair-in-chronic-hives-says-novartis/
China’s Adagene raises $69m for cancer immunotherapiesChinese biotech Adagene has raised $69 million in fourth-round financing to help usher its immuno-oncology drugs – including Share XChina’s Adagene raises $69m for cancer immunotherapieshttps://pharmaphorum.com/news/chinas-adagene-raises-69m-for-cancer-immunotherapies/
Newron plots phase 3 trial of schizophrenia drug after safety scareNewron Pharmaceuticals has clearance to press ahead with phase 3 development of its schizophrenia drug Evenamide after the Share XNewron plots phase 3 trial of schizophrenia drug after safety scarehttps://pharmaphorum.com/news/newron-plots-phase-3-trial-of-schizophrenia-drug-after-safety-scare/
NHS pressures are threatening vital research, says reportMedical research that could have a direct impact on patient care is being blocked by the workload piled Share XNHS pressures are threatening vital research, says reporthttps://pharmaphorum.com/news/nhs-pressures-are-threatening-vital-research-says-report/
NorthSea Therapeutics raises $40m to develop NASH drugDutch biotech NorthSea Therapeutics has raised around $40 million in a series B financing round to help it Share XNorthSea Therapeutics raises $40m to develop NASH drughttps://pharmaphorum.com/news/northsea-therapeutics/
MiNA’s gene-activating tech wins an AstraZeneca allianceUK biotech MiNA Therapeutics’ RNA-based gene-activating technology has caught the eye of big pharma AstraZeneca. AZ has teamed Share XMiNA’s gene-activating tech wins an AstraZeneca alliancehttps://pharmaphorum.com/news/minas-gene-activating-tech-wins-an-astrazeneca-alliance/
Transgene starts trials of ‘digital’ cancer vaccine with NECUndeterred by two clinical failures for its cancer immunotherapies in 2019, Transgene has kicked off the New Year Share XTransgene starts trials of ‘digital’ cancer vaccine with NEChttps://pharmaphorum.com/news/transgene-starts-trials-of-digital-cancer-vaccine-with-nec/
Incyte’s JAK inhibitor for GVHD fails phase 3 trialIncyte’s JAK1 inhibitor itacitinib has failed a key trial in graft-versus-host disease (GVHD), marking another setback for a Share XIncyte’s JAK inhibitor for GVHD fails phase 3 trialhttps://pharmaphorum.com/news/incytes-jak-inhibitor-for-gvhd-fails-phase-3-trial/
